The synergistic contributions of combined GLP-1R and GCGR activation were also evaluated in GLP-1R-null mice maintained on an HFD, in which the dual agonist led to reduced body weight and adiposity due to an anorexic effect while hyperglycaemia was retained; this highlights that a GLP-1 fraction inside the chimeric compound is needed to protect against glucagon-induced hyperglycaemia [215]. Here, GLP1R is linked to Hyperglycemia.